Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2022

View Archived Issues

BUB1 biallelic mutations seen to cause microcephaly and developmental delay

STK26 and DPP4 identified as markers tied to severe COVID-19 risk

Therapeutic CAR T cells generated in the body reduce fibrosis in heart disease model in vivo

Pro-IL-12 could treat tumors with reduced toxicity compared to recombinant IL-12

Discovery of VU-6015241, a novel M4 antagonist with promising preclinical profile

Hefei Amvite Pharmaceutical patents histamine H1 receptor antagonists

Shanghai Antengene discloses new ATR kinase inhibitors

Qilu Regor Therapeutics synthesizes new MAP4K1 inhibitors

Shanghai Medicilon presents new S1PR1 modulators

Jiangsu Simcere Medical Equipment divulges new PRMT5 inhibitors

HCW-9218 potentiates antitumor efficacy by reducing TIS-driven proinflammatory phenotype

IMX-110 + anti-PD-1 extend median survival in genetic pancreatic cancer mouse model

INmune Bio collaborates with CUHK to evaluate INKmune in nasopharyngeal cancer

Siga and Bioarchitech collaborate to study Tpoxx with vaccinia-based immunotherapy platform

Tumorad significantly reduces tumor growth and prolongs survival in colorectal cancer model

MAP-tau map of interactions shows more than microtubules

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...